Singapore - English - HSA (Health Sciences Authority)

bristol-myers squibb (singapore) pte. ltd. - pomalidomide - capsule - pomalidomide 3 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 1 mg - capsule - excipient ingredients: sodium stearylfumarate; mannitol; pregelatinised maize starch; titanium dioxide; indigo carmine; iron oxide yellow; shellac; simethicone; propylene glycol; strong ammonia solution; isopropyl alcohol; butan-1-ol; ethanol absolute; iron oxide black; gelatin - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 4 mg - capsule - excipient ingredients: mannitol; pregelatinised maize starch; sodium stearylfumarate; iron oxide black; shellac; propylene glycol; strong ammonia solution; ethanol absolute; purified water; butan-1-ol; isopropyl alcohol; titanium dioxide; indigo carmine; brilliant blue fcf; gelatin - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

celgene pty ltd - pomalidomide, quantity: 2 mg - capsule - excipient ingredients: mannitol; pregelatinised maize starch; gelatin; titanium dioxide; iron oxide yellow; indigo carmine; erythrosine; iron oxide black; shellac; propylene glycol; strong ammonia solution; ethanol absolute; purified water; butan-1-ol; isopropyl alcohol; sodium stearylfumarate - pomalyst, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide. pomalyst, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

European Union - English - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - pomalidomide - multiple myeloma - immunosuppressants - imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 2 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 4 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide

Israel - English - Ministry of Health

neopharm scientific ltd - pomalidomide - hard capsule - pomalidomide 1 mg - pomalidomide - imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide